diabetestalk.net

Lilly Insulin Pen Online

Up To 51% Off Lilly Insulin Through Blink Health

Up To 51% Off Lilly Insulin Through Blink Health

By Lynn Kennedy, Abigail Dove, and Helen Gao Lilly announces new program, in partnership with Express Scripts, to provide insulin directly to people with diabetes and high out of pocket drug expenses On January 1, Lilly launched a first-of-its-kind program, in partnership with Express Scripts, that offers significant discounts on brand name Lilly insulin to people in the USA with diabetes and high out-of-pocket costs. The program, which shows discounts of up to 51% for some Lilly insulins on Blink Health, will be most impactful for those with high deductible health plans or no insurance [Editor's Note: the original announcement stated that it would be up to a 40% discount on Lilly insulins]. Hopefully, it will also be the first of many efforts to make insulin more affordable; another insulin maker, Novo Nordisk, has already expressed its support for Lilly’s move to spearhead this insulin discount program. Blink Health was originally developed as a tool to help people purchase generic medications at a discount. Lilly’s new program, in partnership with Express Scripts, marks the first time that brand name medications are being sold discounted and direct to consumers on the platform. Anyone with a prescription for Lilly insulin products can receive the discounts through Blink Health. Pens and vials of both analog and human insulins are eligible, including Humalog (insulin lispro U100), Humulin U100, Humalog U200, and Basaglar (biosimilar insulin glargine). It is exciting to see efforts to provide insulin discounts launch, given the public outcry over rising prices and how important it is for the safety and quality of life for people with diabetes to be able to dose correctly. The discounts available through Blink Health exist separate from existing insurance plans. So Continue reading >>

Drug Makers Accused Of Fixing Prices On Insulin

Drug Makers Accused Of Fixing Prices On Insulin

A lawsuit filed Monday accused three makers of insulin of conspiring to drive up the prices of their lifesaving drugs, harming patients who were being asked to pay for a growing share of their drug bills. The price of insulin has skyrocketed in recent years, with the three manufacturers — Sanofi, Novo Nordisk and Eli Lilly — raising the list prices of their products in near lock step, prompting outcry from patient groups and doctors who have pointed out that the rising prices appear to have little to do with increased production costs. The lawsuit, filed in federal court in Massachusetts, accuses the companies of exploiting the country’s opaque drug-pricing system in a way that benefits themselves and the intermediaries known as pharmacy benefit managers. It cites several examples of patients with diabetes who, unable to afford their insulin treatments, which can cost up to $900 a month, have resorted to injecting themselves with expired insulin or starving themselves to control their blood sugar. Some patients, the lawsuit said, intentionally allowed themselves to slip into diabetic ketoacidosis — a blood syndrome that can be fatal — to get insulin from hospital emergency rooms. A recent study in The Journal of the American Medical Association found that the price of insulin nearly tripled from 2002 to 2013. “People who have to pay out of pocket for insulin are paying enormous prices when they shouldn’t be,” said Steve Berman, a lawyer whose firm filed the suit on behalf of patients and is seeking to have it certified as a class action. In a statement, Sanofi said, “We strongly believe these allegations have no merit, and will defend against these claims.” Lilly said it had followed all laws, adding, “We adhere to the highest ethical standards.” Continue reading >>

Eli Lilly Launches Reusable Insulin Pen - Business Line

Eli Lilly Launches Reusable Insulin Pen - Business Line

Eli Lilly enters branded generics segment Eli Lilly and Company India aims to be in the top-20 list of pharmaceutical companies in the nation by 2020, Eli Lilly India MD Edgard A. Olaizola told Business Line here on Tuesday. The company will be bringing in all its diabetes products to the country, Olaizola said. It has launched a new reusable insulin pen, the HumaPen Savvio. India is an important market for us within the emerging markets. In an area like diabetes it is one of the largest markets with about 60 million patients. As a company our vision is to be among the top 20 companies in India by 2020, Olaizola said. The HumaPen Savvio will be priced at Rs 1,000 in the retail market. It will also be provided free of cost to physicians for distribution to patients. The pen will be co-promoted by the Lilly-Boehringer Ingelheim alliance in India. According to Olaiza, the USP of this product which he said resembled an accessory rather than a medical product is that it allows patients to manage the disease discreetly, besides being smaller and having a shelf-life of up to six years. He added that all the diabetes products launched worldwide will be brought to India also in the next few years. It is estimated that the number of diabetics in India will go up to 100 million in 15 years. From a market point of view we have been growing in double digits in the past 3-4 years. Lilly India has been growing faster than the market, he said. The company is also present in segments such as osteoporosis, cardiovascular, oncology and growth hormones. Continue reading >>

Lilly Insulin Prices Come Under Microscope

Lilly Insulin Prices Come Under Microscope

Home Lilly insulin prices come under microscope Lilly insulin prices come under microscope Medical device tax is history, ending years of frustration for Indiana companies Over the past 20 years, while the price of a gallon of milk climbed 23 percent and the sticker on a Dodge Caravan minivan rose 21 percent, the list price of the insulin Humalog, made by Eli Lilly and Co., shot up 1,157 percent. Other Lilly insulins saw hefty price increases, too, including Humulin, on the market since 1982. It has seen price increases totaling nearly 800 percent over the last two decades. The soaring prices at Indianapolis-based Lillyand two other insulin makers, whose prices are climbing at similar ratesare sending sticker shock through the diabetes community. In recent months, patients have filed lawsuits and called for congressional investigations, and now theyre planning a demonstration next month in front of Lillys headquarters on South Delaware Street. The actions are casting a bright glare on Lillys oldest and perhaps most famous franchise. The company was the first to mass produce insulin in the 1920s, a move that allowed it to attract scientists and make other breakthroughs in fields from cancer to depression. Its a critical time for Lilly, as it tries to increase its dominance in the $10 billion diabetes-drug market against chief rivals Sanofi of France and Novo Nordisk of Denmark. Lilly CEO David Ricks continues to point to diabetes as a key area for investment and growth, but the companys ability to keep patients and physicians satisfied could depend on how well it addresses their concerns over prices. Already, some physicians say high insulin prices across the industry are causing financially strapped patients to ration or discontinue their medicines, which could lead to Continue reading >>

Eli Lilly Announces Insulin Discount After Years Of Price Hikes

Eli Lilly Announces Insulin Discount After Years Of Price Hikes

Under pressure from politicians and patient groups, diabetes pharmaceutical giants have been taking action in recent weeks to limit the effect of rising insulin prices on patients. On Tuesday, Eli Lilly and Co. announced that, starting in January, patients who pay full retail price for insulin will be able to access a 40 percent discount. Earlier this month, Novo Nordisk said it would limit its price increases on insulin to a single digit percentage per year. The Eli Lilly discount program will only help people without insurance or who are in the high-deductible phase of a health plan. But the action is part of a widening public discussion among drug companies in response to public scrutiny of its pricing policies. Insulin prices have increased well above inflation over the last two decades. A version of insulin with a list price of $17 a vial in 1997 is priced at $138 today. A two-decade-old insulin that launched at $21 a vial has been hiked to $255. Some industry leaders have argued that unless pharmaceutical companies address problems of access and affordability, they may face government actions that don't benefit them. President-elect Donald Trump recently said that he plans to intervene, although the details of what he might do are not clear. "I'm going to bring down drug prices," Trump told Time. "I don't like what has happened with drug prices." Eli Lilly said that it decided to offer the discount program after months of meeting with leaders in the patient community. People will be able to order the discounted drug through a company called Blink Health, which operates a website and app. "We understand the burden people face when paying full price for insulin," Mike Mason, vice president of Lilly Diabetes said in a statement. Lilly makes several insulin products. Continue reading >>

Lilly Announces Program To Provide Insulin At Discounted Prices

Lilly Announces Program To Provide Insulin At Discounted Prices

Lilly Announces Program to Provide Insulin at Discounted Prices Starting January 1, people who pay the highest out-of-pocket prices for insulin, such as those who pay full retail price at the pharmacy, may directly benefit from 40 percent discount Dec 13, 2016, 06:30 ET from Eli Lilly and Company Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company) (PRNewsFoto/ELI LILLY AND COMPANY) Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company) (PRNewsFoto/ELI LILLY AND COMPANY) INDIANAPOLIS, Dec. 13, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced that people who use Lilly insulin will be able to access discounted prices for their purchases starting January 1, 2017 via mobile and web platforms hosted by Blink Health. The discounts, provided by Lilly through a partnership with Express Scripts (NASDAQ: ESRX ), may reduce costs for people who pay full retail prices at the pharmacy, such as those who have no insurance or are in the deductible phase of their high-deductible insurance plans. Changes in insurance benefit design have increased the cost of insulin for some people. While discounts and rebates paid by manufacturers make insulin affordable for most people, they don't directly help the uninsured or people in the deductible phase of their high-deductible plans. And while some high-deductible plans exempt insulin from the deductible phase, others require people to pay most or all of the retail price until the deductible is met meaning these people don't fully benefit from rebates when they visit the pharmacy. By using the Blink Health platforms, people who pay full price for most Lilly insulins may save 40 percent. This discount program will be the first time branded medicines will be discounted via the Blink Health platform, whic Continue reading >>

New Smart Insulin Pens Making It To Market

New Smart Insulin Pens Making It To Market

In this time of excitement around the acceleration of diabetes technology, it's not all about the Artificial Pancreas. Even the insulin pen injection devices that many of us use are getting smarter, with built-in Bluetooth allowing users to track doses and trends and share that data for a more complete management picture. This isn't a new phenom, as we've seen these "smart pens" in the works for many years. First, we got Lilly's HumaPen Memoir pen several years ago, followed by the Timesulin pen cap, the Echo pen from Novo Nordisk a couple years ago that tracks past doses, and the Bee pen cap most recently. Those are four different approaches to what may be best viewed as "the first generation of smart pens." And now, we're entering the next generation with two new, even more sophisticated connected pen devices coming out: the InPen from Companion Medical in San Diego, which received FDA approval in late July; and the Esysta smart pen from Emperra Digital Diabetes Care in Germany, which was actually launched in early August outside the U.S. and dubs therefore dubs itself "the world's first" insulin pen allowing for automatic data transfer via Bluetooth. Companion Medical’s InPen As a refresher, in May Companion Medical reported that it raised $3.2 million from investors, including Eli Lilly. Here’s a snapshot of the InPen's features we first reported on in July 2015: Contains computer chip technology built right into the base, including Bluetooth LE wireless capability Is refillable using either Lilly or Novo insulin cartridges (the only two types of insulin available in cartridges here in the U.S.) Includes a temperature sensor built into the pen that sets off an app alarm if the pen's temp dips below freezing or above body temperature, ensuring that your insulin i Continue reading >>

Eli Lilly Raised Prices On 9 Drugs Last Week

Eli Lilly Raised Prices On 9 Drugs Last Week

Indianapolis drug giant Eli Lilly raised list prices of nine of its medicines last week between 6 and 10 percent, according to data obtained by CNBC. The increases, taken on May 2, were for drugs including the blood thinner Effient (9.9 percent), the psoriasis drug Taltz (6.9 percent) and the insulins Humalog and Humulin (7.8 percent). The increases fit a pattern at Lilly and many other drugmakers of single-digit percentage hikes once or twice a year, despite political pressure and intense scrutiny of the practices. Lilly has come under fire for the price of its insulin drugs in particular, leading Senator Bernie Sanders to call for a federal investigation into collusion. Lilly and other insulin makers have denied any such activity. Lilly confirmed the price increases in an emailed statement to CNBC, and noted the list prices "do not reflect the significant discounts and rebates that we provide to ensure patients have adequate access to our medicines." "The net price increase that Lilly recognizes is significantly less," spokesman Mark Taylor wrote. "In fact, in 2016, the average discount to list price on our U.S. portfolio rose to 50 percent and net prices rose just 2.4 percent in the U.S." Rebates on list prices of medicines are negotiated by pharmacy benefits managers. Drugmakers argue few patients are exposed to the list prices of medicines because of these discounts and rebates. One of the largest pharmacy benefits managers, Express Scripts, announced this week a program to offer lower drug prices to patients without health insurance or who have high-deductible plans that make out-of-pocket costs for medicines untenable. Lilly's chief executive, Dave Ricks, appeared on CBS This Morning with Express Scripts Chief Tim Wentworth to praise the program, called Inside Rx Continue reading >>

Leeds Formularyformulary

Leeds Formularyformulary

Medicines which are appropriate for initiation and ongoing prescribing in both primary and secondary care. These medicines are considered suitable for GP prescribing following specialist recommendation. Amber Level 2- Specialist Initiation but no monitoring requirements These medicines are considered suitable for GP prescribing following specialist initiation, including titration of dose and assessment of efficacy. Some Amber Level 2 products will have an associated Amber Level 2 Drug Guidance document, available by clicking on the traffic light symbol to the right of the drug name. If this is not available, generic Amber Level 2 Drug Guidance is available here Amber Level 3- Specialist Initiation with ongoing monitoring requirements (Full Amber Drug Guidance required) Medicines that should be initiated by a specialist, and which require significant monitoring on an ongoing basis. Full agreement to share the care of each specific patient must be reached under the amber drug agreement, and Amber Drug Guidance must be provided to the GP (available by clicking on the traffic light symbol to the right of the drug name). Guidance on the responsibilities for Red Drugs can be found here . Red Drugs would usually by prescribed by the hospital for the duration of the course. Primary care prescriber initiation or continuation of treatment not recommended except by Specialist GP and community paediatric prescribing. Grey Drugs are locally-agreed medicines which are only recommended for restricted use within the Leeds Health Economy. These drugs are not recommended for use within the Leeds Health Economy Products shown as blue have different Traffic Light List classifications dependent on indication. See the accompanying text next to the product for further information the indicat Continue reading >>

Humapen From Eli Lilly, Insulin - Actrapid To Human Prodica | Drugsupdate India

Humapen From Eli Lilly, Insulin - Actrapid To Human Prodica | Drugsupdate India

Below are some of the details of Insulin(generic) Insulin is a hormone that is central to regulating energy and glucose metabolism in the body. Insulin causes cells in the liver, muscle, and fat tissue to take up glucose from the blood, storing it as glycogen in the liver and muscle. Insulin stops the use of fat as an energy source. When insulin is absent, glucose is not taken up by body cells and the body begins to use fat as an energy source, for example, by transfer of lipids from adipose tissue to the liver for mobilization as an energy source. As its level is a central metabolic control mechanism, its status is also used as a control signal to other body systems (such as amino acid uptake by body cells). In addition, it has several other anabolic effects throughout the body. When control of insulin levels fails, diabetes mellitus will result. As a consequence, insulin is used medically to treat some forms of diabetes mellitus. Patients with Type 1 diabetes mellitus depend on external insulin (most commonly injected subcutaneously) for their survival because the hormone is no longer produced internally. Patients with Type 2 diabetes mellitus are insulin resistant, and because of such resistance, may suffer from a relative insulin deficiency. Some patients with Type 2 diabetes may eventually require insulin if other medications fail to control blood glucose levels adequately, though this is somewhat uncommon. Insulin also influences other body functions, such as vascular compliance and cognition. Once insulin enters the human brain, it enhances learning and memory and in particular benefits verbal memory. Insulin is a peptide hormone composed of 51 amino acids and has a molecular weight of 5808 Da. It is produced in the islets of Langerhans in the pancreas. The name Continue reading >>

Lilly Launches Kwikpen For Humalog And Humalog Mixtures

Lilly Launches Kwikpen For Humalog And Humalog Mixtures

Indianapolis, IN - Completing an unprecedented year of innovation in insulin delivery devices, Eli Lilly and Company (LLY) recently announced the launch of KwikPen, a new insulin pen prefilled with the Humalog (insulin lispro injection [rDNA origin]) brand of insulins. KwikPen is the third new insulin pen Lilly has launched in the last 12 months to help improve the daily management of diabetes, following the successful launches in 2007 of HumaPen MEMOIR -- the world's first digital insulin pen with memory -- and HumaPen LUXURA HD, a reusable pen for people who need insulin dosing in smaller increments. KwikPen is a prefilled insulin pen designed to be convenient, easy to use and discreet. KwikPen's design can help fit a mealtime insulin, such as Humalog, into the daily lives and routines of people with diabetes. KwikPen is now available by prescription in pharmacies prefilled with the Humalog brand of insulins, including Humalog, Humalog Mix75/25 (75% insulin lispro protamine suspension, 25% insulin lispro injection [rDNA origin]) and Humalog Mix50/50 (50% insulin lispro protamine suspension, 50% insulin lispro injection [rDNA origin]). The Humalog brand of insulins are indicated for use in patients with diabetes to control high blood sugar. Lilly's original Humalog and Humalog Mixtures prefilled pens are also available. Patients using the original Humalog and Humalog Mixtures prefilled pen do not need to convert at this time unless they choose to do so in consultation with a health care professional. "KwikPen, prefilled with Humalog and Humalog Mixtures, provides people with diabetes an exciting new option for accurate insulin dosing with the convenience of an easy-to-use prefilled pen," said Matt Beebe, Humalog Brand Leader, Lilly USA. "We know living with diabetes pr Continue reading >>

Buy Lilly Humapen Ergo Ii Online Insulin Delivery Injection Pen Eli Lilly Best Price On Rxindia

Buy Lilly Humapen Ergo Ii Online Insulin Delivery Injection Pen Eli Lilly Best Price On Rxindia

Defective products that are covered under Seller/Manufacturer's warranty and reported after 10-days. Product or box is damaged due to misuse or incidental damage because of malfunctioning of product. 3. What is the time frame in which, I have to file a return / replacement request? Return/Replace request of the Product(s) to be initiated within 10 days of Delivery. Return Request to be filed with RxIndia's Customer Support within 2 days of Delivery under following condition: It takes between 1 to 3 weeks from the time a request is raised, to the time the product is delivered back to us. Exact time would depend on the nature of the product and your location. Please be assured that we work very hard to ensure that your interests are protected. How should I pack the product for pick up? Do I need to pay the courier company to send my product back? What do I do if my area does not have a reverse pick up service? What are the documents I need to attach for the return / replacement process? My product has been picked up. How do I know it has reached you? 1. How should I pack the product for pick up? Make sure that the merchandise has not been used/altered/tampered with, as well as is accompanied by its original price tag and packing slip. Do not forget to mention your order number on the box. If your order is approved for pickup, you will receive the packaging instructions, return address and documentation needed, in a separate email from us. 2. Do I need to pay the courier company to send my product back? No, if we arrange the pickup of your product, you don't need to pay anything. If you are using a courier service to send your product back, you need to bear the courier cost, which will be reimbursed by us in form of RxPoints. The courier charges eligible for reimbursement Continue reading >>

Soaring Insulin Prices Have Diabetics Feeling The Pain

Soaring Insulin Prices Have Diabetics Feeling The Pain

Insulin price spike leads to lawsuitInsulin is fast becoming a medication that only the well-insured or well-heeled diabetic can afford. With the price of insulin more than tripling in a decade, some diabetics are having to make tough choices about how to pay for the medication. In some cases, diabetics are cutting back or even going without the drug. Many of the 26 million Americans with diabetes must use insulin daily to treat the disease, or else risk illnesses such as kidney failure and disabilities such as blindness. While American diabetics may have faced monthly costs of $100 to $200 several years ago, some are now grappling with costs of $400 to $500 per month. Insulin prices for American patients are far higher than in other countries, a recent survey of patients from the advocacy group T1International discovered. American diabetics said they pay $13.47 per milliliter for Eli Lilly’s (LLY) Humalog insulin, the highest price among the countries surveyed and about four times more than what Canadian diabetics pay. “People are suffering a lot,” said Allison Bailey, a college student in Iowa with Type 1 diabetes. “There are no generics. We have to go through these big companies, and they charge so much.” Bailey said she paid about $130 for several vials of Eli Lilly’s Humalog in 2010. This year, her insulin prescription has a price tag of about $495. She noted that she switched from using pump therapy in 2010 and now injects insulin with a pen, and that while the prices aren’t apples-to-apples, costs have overall sharply increased. She said she should go back to pump therapy, but she doesn’t believe she can afford it given the higher cost of insulin as well as the expense of a pump, which can cost more than $5,000. Others are also caught in a bind. B Continue reading >>

Flexpen® And Kwikpen™ Prefilled Insulin Devices: A Laboratory Evaluation Of Ergonomic And Injection Force Characteristics

Flexpen® And Kwikpen™ Prefilled Insulin Devices: A Laboratory Evaluation Of Ergonomic And Injection Force Characteristics

Go to: Abstract Advances in insulin pen technology continue to improve the usability of these devices for patients with diabetes. In this study, ergonomic features and injection force, as measured by glide force (GF) and glide force variability (GFV), were evaluated for the new Humalog® Mix75/25 KwikPen™ (KwikPen) and compared with the NovoLog® Mix 70/30 FlexPen® (FlexPen). Fifty prefilled insulin pen devices (25 of each type) were measured for diameter at the cartridge holder and dose window, length and weight with cap attached, and thumb reach at 30 and 60 units. GF was also determined for 100 devices (50 of each type); GFV at 30 and 60 unit doses was calculated for the plateau portion of the force curve based on the minimum and maximum force measured in that portion of the curve. While FlexPen was lighter in weight than KwikPen, and presented a slightly smaller diameter at the cartridge holder and dose window, KwikPen had a shorter overall pen length compared to FlexPen, with a shorter thumb reach at both the 30- and 60-unit dose settings. The maximum GF for KwikPen was less than FlexPen at both the 30-unit (3.42 vs 5.36 lb, p <0.0001) and 60-unit doses (3.61 vs 5.62, p <0.0001). KwikPen GFV was lower across both doses (mean difference: −0.46 lb at 30 units, −0.44 lb at 60 units; p <0.0001 for both). While FlexPen was lighter with a slightly smaller cartridge holder and dose window diameter, KwikPen was shorter in length with less thumb reach than FlexPen. KwikPen also demonstrated lower GF and GFV, resulting in a smoother injection profile than FlexPen. These features of KwikPen's design and function may offer important advantages for the user during insulin administration. Keywords: ergonomic, glide force, injection force, insulin pen Continue reading >>

Eli Lilly Humalog Manufacturing Facility, Carolina

Eli Lilly Humalog Manufacturing Facility, Carolina

Eli Lilly began production of the insulin product Humalog at its new bulk manufacturing facility in Carolina, Puerto Rico, in mid-2005. Scanning electron micrograph of E. coli as used for recombinant DNA techniques. Pro-insulin and human insulin, showing where the trypsin cleavage occurs. In April 2001 Eli Lilly announced it was constructing a new biotech bulk manufacturing facility in Carolina, Puerto Rico. Construction started in July 2002 and, following validation and commissioning, the plant was in production by mid-2006. This project was part of an overall $1bn investment into the company’s facilities in Puerto Rico, which was completed in August 2006. The 300,000ft² facility produces the rapid-acting insulin product Humalog, dispensed from the KwikPen (MirioPen), which is manufactured in Indianapolis. The production of this requires the use of recombinant DNA technology via insulin lispro [rDNA origin] injection. KwikPens became available for Humalog, Humalog Mix75/25 and Humalog Mix50/50 in February 2008. KwikPen is the third new insulin pen launched since 2007 to improve the daily management of diabetes. Previous models include the HumaPen MEMOIR, the world’s first digital insulin pen with memory; and HumaPen LUXURA HD, a reusable pen for patients who need insulin dosing in smaller increments. In February 2010, the plant was issued a warning letter by the US Food and Drug Administration (FDA) for deviations in cGMP API production. The FDA cited deviations during an inspection conducted in 2009. Deviations were found in 24 batches of Lyspro Insulin Zinc Crystals, the API in Humalog, released between December 2007 and March 2008. Production of the original Humalog pre-filled pens including the Humalog Mix75/25 and the Humalog Mix50/50 was discontinued Continue reading >>

More in diabetes